SNY and it's commitment to its partners
Jul 28, 2015 6:37:38 GMT -5
kc, Chris-C, and 1 more like this
Post by joeypotsandpans on Jul 28, 2015 6:37:38 GMT -5
While one thing is not dependent on the other in this particular case, it does show when they like who their in bed with they seem to want to further the relationship. I have never been in the camp of the definitive "buy in" or "buy out" reason for being invested in MNKD BUT I have always been in the camp that they (AL) chose the best possible partner. With today's announcement by SNY regarding their furthering their relationship with REGN...it does show me they act when they see good things with their partners 
Sanofi, Regeneron Enter Major New Immuno-Oncology Collaboration
2:07 am ET July 28, 2015 (Dow Jones) Print
By Noemie Bisserbe
PARIS--French drug maker Sanofi SA (SAN.FR) said Tuesday it had entered into a new research agreement with Regeneron Pharmaceuticals Inc. and agreed to invest $2.17 billion to jointly develop new cancer treatments.
Sanofi will make an upfront payment to Regeneron of $640 million. Sanofi and Regeneron will invest $750 million and $250 million respectively, to develop new monotherapy and novel combinations of immuno-oncology antibody experimental drugs.
Each company will also invest an additional $325 million to develop REGN2810, a so-called PD-1 inhibitor--a drug that blocks a protein called programmed death receptor 1, or PD-1, which acts as a brake on certain immune-system cells to prevent them from attacking healthy tissue.
In the event that sales of a PD-1 product, or any other drug sold for use in combination with a PD-1 product, exceed $2 billion in any consecutive 12-month period, Sanofi will pay to Regeneron a one-time milestone of $375 million.
Sanofi, Regeneron Enter Major New Immuno-Oncology Collaboration
2:07 am ET July 28, 2015 (Dow Jones) Print
By Noemie Bisserbe
PARIS--French drug maker Sanofi SA (SAN.FR) said Tuesday it had entered into a new research agreement with Regeneron Pharmaceuticals Inc. and agreed to invest $2.17 billion to jointly develop new cancer treatments.
Sanofi will make an upfront payment to Regeneron of $640 million. Sanofi and Regeneron will invest $750 million and $250 million respectively, to develop new monotherapy and novel combinations of immuno-oncology antibody experimental drugs.
Each company will also invest an additional $325 million to develop REGN2810, a so-called PD-1 inhibitor--a drug that blocks a protein called programmed death receptor 1, or PD-1, which acts as a brake on certain immune-system cells to prevent them from attacking healthy tissue.
In the event that sales of a PD-1 product, or any other drug sold for use in combination with a PD-1 product, exceed $2 billion in any consecutive 12-month period, Sanofi will pay to Regeneron a one-time milestone of $375 million.
